Publication:
Effects of hydroxychloroquine plus favipiravir treatment on the clinical course and biomarkers in hospitalized covid-19 patients with pneumonia

dc.contributor.authorKASAPOĞLU, UMUT SABRİ
dc.contributor.authorsAcun Delen L., Gök A., Kasapoğlu U. S., Çağaşar Ö., Ekici Gök Z., Berber N., Derya S., Tetik B.
dc.date.accessioned2023-03-24T12:40:35Z
dc.date.accessioned2026-01-11T14:00:44Z
dc.date.available2023-03-24T12:40:35Z
dc.date.issued2022-11-01
dc.description.abstractSUMMARY – Background: The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clinical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumonia. Unfortunately, the optimal treatment approach is still uncertain. However, many studies have been conducted on the effectiveness of several medications in the treatment of COVID-19 infection. The aim of this study was to evaluate the effectiveness of the hydroxychloroquine (HCQ) + favipiravir (FAV) treatment regimen and HCQ alone by comparing the patient’s clinical response and laboratory results on the fifth day of treatment in patients hospitalized due to COVID-19 infection. Patients and methods: This retrospective cohort study was conducted in Malatya Training and Research Hospital between March 2020 and July 2020. The study included 69 patients with confirmed COVID-19 with pneumonia. The patients were divided into 2 groups, those receiving HCQ alone and those receiving the HCQ + FAV combination. Results: A total of 69 patients were included in the study, and the mean age was 60.09±15.56 years. A statistically significant decrease was observed in C-reactive protein (CRP) levels, at the end of the fifth day, in patients who received HCQ + FAV treatment (p=0.002), whereas there was no decrease in CRP levels in patients who received HCQ treatment alone. In addition, an increase in lymphocyte count and a better fever response was observed at the end of the fifth day in patients who received HCQ + FAV (p=0.008). However, there was no statistical difference between both treatment regimens in terms of hospital stay and treatment results (p=0.008, p=0.744, p=0.517). Conclusion: Although the combination of HCQ + FAV treatment was observed to be effective on CRP levels and fever response in patients with COVID-19 pneumonia, there was no difference in terms of hospital stay and discharge.
dc.identifier.citationAcun Delen L., Gök A., Kasapoğlu U. S., Çağaşar Ö., Ekici Gök Z., Berber N., Derya S., Tetik B., "Effects of Hydroxychloroquine Plus Favipiravir Treatment on the Clinical Course and Biomarkers in Hospitalized COVID-19 Patients with Pneumonia", ACTA CLINICA CROATICA, cilt.61, sa.3, ss.403-411, 2022
dc.identifier.doi10.20471/acc.2022.61.03.05
dc.identifier.endpage411
dc.identifier.issn0353-9466
dc.identifier.issue3
dc.identifier.startpage403
dc.identifier.urihttps://hrcak.srce.hr/en/file/428402
dc.identifier.urihttps://hdl.handle.net/11424/287778
dc.identifier.volume61
dc.language.isoeng
dc.relation.ispartofACTA CLINICA CROATICA
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectİç Hastalıkları
dc.subjectYoğun Bakım
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectChest Diseases and Allergy
dc.subjectInternal Diseases
dc.subjectIntensive Care
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectSOLUNUM SİSTEMİ
dc.subjectYOĞUN BAKIM
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectRESPIRATORY SYSTEM
dc.subjectCRITICAL CARE MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectSolunum Bakımı
dc.subjectGenel Sağlık Meslekleri
dc.subjectPatofizyoloji
dc.subjectTemel Bilgi ve Beceriler
dc.subjectDeğerlendirme ve Teşhis
dc.subjectAkciğer ve Solunum Tıbbı
dc.subjectDahiliye
dc.subjectAile Sağlığı
dc.subjectYoğun Bakım Tıbbı
dc.subjectTıp (çeşitli)
dc.subjectGenel Tıp
dc.subjectRespiratory Care
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectFundamentals and Skills
dc.subjectAssessment and Diagnosis
dc.subjectPulmonary and Respiratory Medicine
dc.subjectInternal Medicine
dc.subjectFamily Practice
dc.subjectCritical Care and Intensive Care Medicine
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectFavipiravir
dc.subjecthydroxychloroquine
dc.subjectCOVID-19
dc.subjectSARS-COV-2
dc.subjectpneumonia
dc.titleEffects of hydroxychloroquine plus favipiravir treatment on the clinical course and biomarkers in hospitalized covid-19 patients with pneumonia
dc.typearticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
301.17 KB
Format:
Adobe Portable Document Format